Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-14 · accession 0000905148-24-001483 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-16 | 2024-05-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $8.36 | -54.9K | 2.56M | -2% | -$459.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-14 | F | D | 54,918 | $8.36 | 2,561,894 | D | — | — |